DICE Therapeutics, Inc.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulat…
Biotechnology
US, South San Francisco [HQ]
DICE/Financial Reporting
Income Statements
4 Sheets · Starting from 2022In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Revenue | 5.00 | - - | 1.00 | - - | |
|
EPS
|
-0.56 | -1.02 | -3.91 | -2.07 | |
| Diluted in mil. | -0.56 | -1.02 | -3.91 | -2.07 | |
|
Profit
|
5.00 | - - | 1.00 | - - | |
| Gross Margin | 100.00 | 100.00 | 100.00 | - - | |
| Pre Tax | -12.00 | -23.00 | -48.00 | -83.00 | |
| Profit Margin | -224.03 | -2,750.75 | -4,351.91 | - - | |
| ETR | -0.20 | -0.05 | 0.99 | 2.65 | |
| Net | -12.00 | -23.00 | -48.00 | -81.00 | |
| Profit Margin | -224.48 | -2,752.26 | -4,308.62 | - - | |
| EBITDA | -12.00 | -22.00 | -47.00 | -83.00 | |
| EBITDA Margin | -211.36 | -2,651.80 | -4,219.29 | - - | |
| Operating Income | -13.00 | -23.00 | -47.00 | -88.00 | |
| Operating Margin | -234.58 | -2,748.67 | -4,231.38 | - - | |
| Interest Income | - - | - - | - - | 5.00 | |
| Loss | -19.00 | -24.00 | -48.00 | -88.00 | |
| Cost of Revenue | - - | - - | - - | - - | |
|
Operating Expenses
|
-19.00 | -24.00 | -48.00 | -88.00 | |
| R&D | -15.00 | -19.00 | -36.00 | -62.00 | |
| G&A | -3.00 | -5.00 | -12.00 | -25.00 | |
| SG&A | -3.00 | -5.00 | -12.00 | -25.00 | |
| S&M | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | -2.00 | |
| Interest Expenses | - - | - - | - - | - - | |
| Other Expenses | - - | - - | -1.00 | -4.00 | |
|
WA Shares Outstanding
|
23.00 | 23.00 | 12.00 | 39.00 | |
| Diluted | 23.00 | 23.00 | 12.00 | 39.00 |